Glaucoma Treatment to Stop Vision Loss
As glaucoma is a leading cause of irreversible vision loss, there is a growing need to address this condition. People are living longer and current solutions have a limited lifespan. Allevio’s solution is simple, minimally invasive, and fast — reducing surgical time when compared with other shunt procedures.
Glaucoma affects 80 million people and $3.4 billion is currently spent annually in the United States treating this disease in the form of both drug therapy and surgery. Alievio’s shunt helps prevent vision loss with a solution that is superior to existing prescription drug therapies and surgical treatments. The device is patented and initial trials have produced positive results. The implantation of the shunt is simple, minimally invasive, and reduces surgical time when compared with other shunt procedures.
Quick Facts for Investors
Why We Invested
The CEO was the former COO at Summit Technology, the first company to bring PRK/LASIK to the market.
The company previously raised $2.6 million in non-dilutive funding (grants) and $7M in equity funding. Co-investors include InFocus Capital Partners which was founded by two ophthalmologists who only invest in eye-related tech.
“Carmras Vision’s shunt will transform the way I do surgery. It is extremely innovative and a game-changer.”
~ Dr. Robert Rothman, a Clinical Assistant Professor of Ophthalmology at New York Medical College, The New York Eye and Ear Infirmary, and Hofstra Medical School